

CME QUESTIONS

This issue of *TraumaCare* can be used to earn 10 CME credit hours.

Accreditation Statement

This activity has been planned and produced in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the International Trauma Anesthesia and Critical Care Society (ITACCS). ITACCS is accredited by the ACCME to sponsor continuing medical education (CME) for physicians and takes responsibility for the content, quality, and scientific integrity of this CME activity.

Credit Designation Statement: ITACCS designates this educational activity for a maximum of 10 hours per issue in category 1 credit toward the AMA Physician's Recognition Award.

Nurse Anesthetists/CRNAs: Please apply to AANA for post-activity continuing education credits. Certificates of completion will be provided.

Faculty Disclosure Statement

It is the policy of ITACCS that faculty members disclose real or apparent conflict of interest relating to the topics of this educational activity and also disclose discussions of unlabeled/unapproved uses of drugs or devices in their presentations. The authors' completed disclosure forms are on file in the managing editor's office.

INSTRUCTIONS

- The answer grid and evaluation form may be submitted as the page from the printed journal or as a printout from the ITACCS web site.
- On the answer form at the bottom of page 99, circle only one response next to each number.
- Complete the evaluation form.
- Cut out or copy your completed answer form and evaluation form.
- Write a check for \$200 (or \$100 accompanied by verification of current ITACCS membership), payable to the International Trauma Anesthesia and Critical Care Society.
- Mail the forms and your check (and membership verification, if applicable) to ITACCS, Department of CME Credit, PO Box 4826, Baltimore, MD 21211.
- The completed test will be accepted for grading if received by October 31, 2004.
- Please allow 4 to 6 weeks for processing.

CME QUESTIONS

1. In a rescue scenario with helicopter landing being impossible due to a steep decline, an in-and-out hover manoeuvre can be one of the possible techniques to load a patient into a helicopter.
 - a. True
 - b. False
2. What NACA score would be applicable to a patient after successful CPR?
 - a. NACA 6
 - b. NACA 7
 - c. NACA 1
 - d. NACA 3
3. How many NACA grades are there?
 - a. 5
 - b. 4
 - c. 3
 - d. 7
4. A patient opens his eyes to painful stimulus, groans, and localizes to pain. What is his GCS score?
 - a. 7
 - b. 9
 - c. 6
 - d. 11
5. What are the clinical signs of tension pneumothorax?
 - a. respiratory distress
 - b. tachycardia
 - c. tracheal deviation
 - d. unilateral absence of breath sounds
 - e. all of the above
6. The estimated probability of death of a 45-year-old man with a 45% TBSA burn and inhalation injury is 33%.
 - a. True
 - b. False
7. The most important aspect of immediate treatment of a chemical burn is neutralizing acids with alkalis and alkalis with acids.
 - a. True
 - b. False
8. Tracheostomy may be performed through grafted tissue after 24 to 48 hours from grafting.
 - a. True
 - b. False
9. Steroids have been shown to be safe and effective in treating chemical airway injury.
 - a. True
 - b. False
10. The most important mechanism of carbon monoxide poisoning is its binding to cytochrome C.
 - a. True
 - b. False
11. The Parkland formula for fluid resuscitation consists of giving lactated Ringer's solution at a rate of 4 ml/kg/TBSA%burn/hr.
 - a. True
 - b. False

- 12. The most significant risk factor for the development of nosocomial infection is tracheal intubation.
a. True b. False
- 13. Therapeutic considerations for superficial and deep second-degree burns are almost the same.
a. True b. False
- 14. Infants and small children are at increased risk of developing hypocalcemia secondary to blood transfusion.
a. True b. False
- 15. An important pathway that plays a role in inflammation is initiated by which factor?
a. NF-kB b. TGF-Bc. EGF d. GH
- 16. Which protein that has potent anticoagulant properties coats endothelial cells and plays a role in coagulation?
a. FVII b. FVIX c. Annexin d. TF
- 17. Which cell type plays an important role in coagulation and becomes activated during the coagulation process?
a. Endothelial cells b. Platelets c. White blood cells d. Endometrial cells
- 18. What is the second leading cause of death in trauma patients?
a. Exsanguination b. Infection c. Heart attack d. Sepsis
- 19. Which of the following is the latest technology to stop bleeding, which will be entering clinical trials soon?
a. Gelfoam b. rFVIIa c. Dry fibrin compresses d. None of the above
- 20. What dosage range of rFVIIa is utilized in Europe in shock/trauma clinical trials?
a. 40 µg/kg to 100 µg/kg b. 80 µg/kg to 180 µg/kg c. 100 µg/kg to 200 µg/kg d. 200 µg/kg to 380 µg/kg

Evaluation Form: Please rate this self-study activity by marking one response for each statement.

Did the articles meet their stated objectives? ___Yes ___No

How do you rank the quality of this educational activity? ___5 (high) ___4 ___3 ___2 ___1 (low)

Comments: _____

Did you perceive any evidence of bias for or against any commercial products? ___Yes ___No If yes, please explain.

Comments: _____

How do you rank the effectiveness of this activity as it pertains to your practice? ___5 (high) ___4 ___3 ___2 ___1 (low)

Did this material stimulate your intellectual curiosity? ___5 (high) ___4 ___3 ___2 ___1 (low)

Additional comments about this activity:

Answer Form: Please circle the one best answer for each question.

TraumaCare Summer 2003 issue

Name: _____
 Address: _____

 City: _____
 State: _____ Zip: _____ Phone: _____

I certify that I have completed the "TraumaCare/Summer 2003" activity as designed and claim 10 credit hours in Category 1 of the Physicians Recognition Award of the American Medical Association.

Signature _____ Date _____

Mail answer form and check (\$100, members; \$200, nonmembers) to ITACCS Department of CME Credit, P.O. Box 4826, Baltimore, MD 21211. Allow 4 to 6 weeks for processing.

- 1. a b 11. a b
- 2. a b c d 12. a b
- 3. a b c d 13. a b
- 4. a b c d 14. a b
- 5. a b c d e 15. a b c d
- 6. a b 16. a b c d
- 7. a b 17. a b c d
- 8. a b 18. a b c d
- 9. a b 19. a b c d
- 10. a b 20. a b c d

Credit for this activity is offered until October 31, 2004.

Bringing Simulation to Life



Laerdal SimMan™

There is a growing awareness that health care is behind other high risk operations in its attention to ensuring basic safety and that there is a need to grasp the scale of the problem (1,2).

Use of patient simulation is considered an important part of the solution as many scenarios can be presented including uncommon but critical situations where a rapid response is needed. Errors can be allowed to occur and reach their conclusion without any risk to a patient. Team member interactions and leadership can also be explored and developed.

Two new manikin-based simulators from Laerdal, SimMan™ and AirMan™, represent a new generation of affordable and portable solutions to meet these needs.

References:

- 1) BMJ Volume 320, 18 March 2000
- 2) To Err Is Human: Building a Safer Health System/Linda T. Kohn, Janet M. Corrigan, and Molla S. Donaldson, Editors, © 2000 by the National Academy of Sciences.

For more information, request a free CD-demo or visit www.laerdal.com/simman

LAERDAL MEDICAL AS, PO. Box 377, N-4002 Stavanger, Norway
Tel 47-51 51 17 00, Fax 47-51 52 35 57, E-mail laerdal.norway@laerdal.no



Laerdal
helping save lives